Nippon Gases Italia and Noxtec Development join forces to develop and strengthen a company dedicated to design, produce and distribute state-of-the-art medical devices worldwide.
This partnership stems from the desire of the two companies to embark together on a path, already started separately in recent years, aimed at the technological improvement of devices used in inhaled nitric oxide therapies, thanks to a continuous exchange of information with university and hospital structures, in order to improve their effectiveness and evaluate the development of new applications.
The ambition of the new venture is to meet the needs of the nitric oxide therapy market, which has grown exponentially in recent years, concentrating first in neonatal intensive care units, then in pediatric and adult settings, and finally playing a key role during the last 2 years in the treatment of Covid-19 patients.
The increased use of Nitric Oxide, a powerful vasodilator, is linked not only to its effectiveness in terms of therapy response times, but above all to its localized action in the cardiopulmonary area, lowering blood pressure rapidly and avoiding interactions with other areas of the human body.
The new joint venture will combine Noxtec Development's high-level expertise in the development of new high-tech medical products with Nippon Gases' 100 years of experience in the production of medical gases. Nippon Gases, acquiring the controlling share of the company, will give wide geographical reach and visibility of the new project all over the world with the goal of exploring new geographies and the aim to create social value through innovative solutions.
Inhaled nitric oxide therapy equipment will be just one of the milestones of the new company, which will focus on innovation to improve the quality of medical products and services for healthcare providers and patients, enhancing human well-being and contributing to a more sustainable future.
The company will be a reference in the medical sector, relying on a competent, experienced and dedicated team focused on the core values of both partners: reliability, quality, safety and sustainability.
Nippon Gases, one of the leading industrial and medical gases companies in Europe, is part of the Nippon Sanso Holdings Corporation, which has over 100 years of experience and boasts a major presence in Japan, the United States and Canada, Europe, South East Asia and Australia, operating in 31 countries with more than 19,000 employees around the world. Our presence in Europe positions us as a leading company with over 3,000 employees of which 27% are women, operating today in 13 countries and serving more than 150,000 customers.
Nippon Gases Italia, founded in 1920 as Rivoira, is one of the main players operating in the medical gases sector. Through Nippon Gases Pharma, the Group's company that produces and markets medical gases for both hospital and homecare, we provide patients and customers safe and reliable quality products and services.
Noxtec Development, established in 2017 to develop new products in the high-tech medical sector, has over the years developed a strong specialization in the field of inhaled nitric oxide therapies.
The first device for inhaled nitric oxide therapies, developed by Noxtec, has made it possible not only to monitor and manage the therapy in constant doses as the patient's respiratory flow changes, but also to improve the safe management of the device through remote control systems and automatic calibration.